Overview Financials News + Filings Key Docs Charts Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Asset disposition Auditor change Employment agrmnt Quarterly results Appointed director CC transcript
|
YIELD10 BIOSCIENCE, INC. (YTEN)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
08/14/2023 |
8-K
| Quarterly results |
11/14/2022 |
8-K
| Quarterly results |
08/10/2022 |
8-K
| Quarterly results |
05/11/2022 |
8-K
| Quarterly results |
11/10/2021 |
8-K
| Quarterly results |
05/11/2021 |
8-K
| Quarterly results |
11/12/2020 |
8-K
| Quarterly results |
08/11/2020 |
8-K
| Quarterly results |
05/14/2020 |
8-K
| Quarterly results |
11/12/2019 |
8-K
| Quarterly results |
08/12/2019 |
8-K
| Quarterly results
Docs:
|
"Yield10 Bioscience Announces Second Quarter 2019 Financial Results WOBURN, Mass. - August 12, 2019 - Yield10 Bioscience, Inc. , an agricultural bioscience company which uses its “Trait Factory” to develop high value seed traits for the agriculture and food industries, today reported financial results for the three and six months ended June 30, 2019. "We have focused on executing against our business strategy and have made considerable progress positioning Yield10 for multiple proof points and catalysts in 2019,” said Oliver Peoples, Ph.D., president and chief executive officer of Yield10 Bioscience. “With our 2019 field tests underway and the deployment of our novel yield traits in progress in crops including canola, soybean and corn, we expect to generate proof points including agronomic,..." |
|
05/09/2019 |
8-K
| Quarterly results |
11/08/2018 |
8-K
| Quarterly results
Docs:
|
"Yield10 Bioscience Announces Third Quarter 2018 Financial Results WOBURN, Mass. - November 8, 2018 - Yield10 Bioscience, Inc. , a Company developing new technologies to achieve step-change improvements in crop yield to enhance global food security, today reported financial results for the three and nine months ended September 30, 2018. "During the third quarter we continued to execute on our key objectives for 2018 as we signed a new research license with Forage Genetics for testing our yield traits in sorghum, clarified the regulatory path for genome-edited plants containing multiple edits, and advanced our yield traits in development," said Oliver Peoples, Ph.D., President and Chief Executive Officer of Yield10 Bioscience. "As the end of the year approaches, we plan to report out results..." |
|
08/09/2018 |
8-K
| Quarterly results |
05/10/2018 |
8-K
| Quarterly results |
11/09/2017 |
8-K
| Quarterly results |
08/10/2017 |
8-K
| Quarterly results |
05/11/2017 |
8-K
| Form 8-K - Current report |
11/09/2016 |
8-K
| Quarterly results |
11/05/2013 |
8-K
| Quarterly results |
11/01/2012 |
8-K
| Quarterly results |
07/26/2012 |
8-K
| Form 8-K - Current report |
04/26/2012 |
8-K
| Quarterly results |
11/01/2011 |
8-K
| Form 8-K - Current report |
07/27/2011 |
8-K
| Quarterly results |
04/27/2011 |
8-K
| Quarterly results
Docs:
|
"METABOLIX, INC. CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS UNAUDITED Three Months Ended March 31, 2011 2010 Revenue: License fee and royalty revenue from related parties $ 301 $ 30 Grant revenue 25 — Research and development revenue — 150 Total revenue 326 180 Operating expense: Research and development expenses, including cost of revenue 6,199 6,168 Selling, general, and administrative expenses 3,787 3,869 Total operating expenses 9,986 10,037 Loss from operations Other income: Interest income, net 20 55 Net loss $ $ Net loss per share: Basic and Diluted $ $ Number of shares used in per share calculations: Basic and Diluted 26,904,606 26,536,924 METABOLIX, INC. CONDENSED CONSOLIDATED BALANCE SHEET UNAUDITED March 31, December 31, 2011 2010 Assets Cash, cash equivalents and short-term..." |
|
11/08/2010 |
8-K
| Form 8-K - Current report |
07/28/2010 |
8-K
| Form 8-K - Current report |
04/28/2010 |
8-K
| Quarterly results |
10/29/2009 |
8-K
| Quarterly results |
07/29/2009 |
8-K
| Quarterly results
Docs:
|
"Metabolix Reports Second Quarter Financial Results and Provides Business Update Cambridge, Massachusetts, July 29, 2009. Metabolix, Inc. , a bioscience company focused on developing clean, sustainable solutions for plastics, chemicals and energy, today reported financial results for the three months ended June 30, 2009. The Company reported a net loss of $9.7 million or $0.42 per share for the second quarter of 2009 as compared to a net loss of $8.9 million or $0.39 per share for the second quarter of 2008. The Company's net cash used for operating activities during the second quarter of 2009 was $4.0 million, which compares to net cash used of $3.8 million for the comparable quarter in 2008. Unrestricted cash and short-term investments at June 30, 2009 totaled $77.6 million. The Company h..." |
|
05/06/2009 |
8-K
| Quarterly results |
11/05/2008 |
8-K
| Quarterly results |
08/11/2008 |
8-K
| Quarterly results |
|
|
|